The medical and mental health community speak out about the dangers of “antipsychotic” drugs and proven, non-drug alternatives

The medical and mental health community speak out about the dangers of “antipsychotic” drugs and proven, non-drug alternatives

A couple of decades ago, big pharma promised to revolutionize the treatment of serious mental health concerns with a new class of atypical antipsychotic drugs such as Abilify and Seroquel. In terms of financial success, those two drugs were “revolutionary.” They are now the 5th and 6th most commonly prescribed drugs in America — despite mounting evidence that questions the efficacy and safety of these drugs (e.g. the huge CATIE and CUtLASS trials). Prominent members of the psychological and psychiatric communities are sounding the alarm about the overuse of these drugs and the erosion of other forms of treatment, particularly evidence-based psychosocial approaches.

In a recent article in the New York Times, Richard Friedman, M.D., expresses concern over increasing use of these drugs for unproven conditions, calling the use of “antipsychotic” drugs to treat everything from anxiety to insomnia as “unbelievable.” Studies on the use of antipsychotics to treat anxiety have failed to show that they are effective and there is no FDA approval for any atypical antipsychotic for the treatment of any anxiety disorder. Despite this lack of evidence, a recent study showed that prescribing of antipsychotics by psychiatrists for anxiety almost doubled between 1996 and 2007.  In this study, 21% of individuals who sought treatment from a psychiatrist for an anxiety disorder in 2007 were prescribed an antipsychotic drug versus  11% in 1996. Moreover, as Dr. Friedman points out, antipsychotics, including  newer “atypical” drugs, frequently have serious side effects such as increased blood lipids and cholesterol, irreversible movement disorders, and weight gain. If these statistics are correct, there are hundreds of thousands of people in the US alone who are taking antipsychotic medications for conditions they have been shown to not work with and suffering under the serious side effects of these medications.

Dr. Friedman is not alone in sounding the alarm. Just this year, the editor of the British Journal of Psychiatry (BJP), probably the most influential psychiatry journal in Britain, called for an “end to the psychopharmacological revolution.” In this piece in BJP, he stated that the prescription of antipsychotic medications needs to be drastically reduced. He stated that the side effects of antipsychotic drugs are too extreme to justify their limited benefit, even in the treatment of schizophrenia and bipolar disorder, for which there exists the largest evidence base supporting the use of these drugs. He stressed that non-drug therapies, such as cognitive behavioral therapy, are proven, effective, and affordable alternatives that need to be used much more frequently. This statement comes from someone who is a prominent member of the medical and psychiatric communities, where drug treatments are usually preferred over psychosocial interventions.

Psychological treatments for schizophrenia, anxiety, and other mental health conditions continue to advance and are becoming more readily available. Based on the current state of the evidence on the use of antipsychotics and the rapidly growing evidence for the use of psychological versus pharmacological treatments, consumers of mental health services need to understand that there are effective alternatives to medications. While it is our opinion that there can be a role for medication in the treatment of mental health difficulties, we want consumers to be informed about the limited effectiveness of antipsychotics, the large potential downsides of using this kind of medication, and the availability of effective psychological treatments. Big pharma is not going to send this message, and people need to be able to make informed choices about their mental health care.

Many in the scientific community are sounding the alarm about the rapidly growing use of antipsychotic medications. But is that alarm loud enough to be heard above the incredibly well-funded big pharma marketing campaigns? We hope so.

UPCOMING TRAINING EVENTS


De-Mystifying Self-As-Context in ACT: Practical Strategies for Clients

Brian Pilecki, PhD and Kati Lear, PhD
December 3rd, 2021 from 12pm-1:30pm

This workshop will outline how self-as-context can be used to conceptualize commonly discussed topics in therapy such as self-esteem, confidence, identity, and inner conflict. Participants will learn how to flexibly practice practical self-as-context interventions that can be used with clients, as well as have a chance to practice newly learned skills through structured role-play exercises in breakout groups. Read More.


Values in Therapy: An Intro to Working with Values from an ACT Perspective

Jenna LeJeune, PhD
January 21, 2022 from 12pm-2:00pm

This workshop will provide a theoretical and conceptual overview of values from a contextual behavioral science perspective. We will cover the “what”, “why”, “when”, and “how” of values within ACT. While we will also provide an overview of various values exercises and measures that can be used with clients, the emphasis in this workshop will be on providing a foundational framework that will help clinicians approach values work from a functional perspective rather than a primarily technique-focused approach. Read More.



Culturally Responsive Therapy: How to Apply Anti-Racist Values in Session

Christy Tadros, LPCC and RaQuel Neal, LCSW
February 4th, 2022 from 1:30pm-4:45pm
and February 5th from 9:00am-12:00pm

This 2 day 6-hour training will help therapists develop their ability to support clients from a different racial background than them, with a particular focus on Black, Indigenous and People of Color. Through a multicultural social justice framework, it will integrate research and clinical experience to teach a therapeutic model for rapport building, assessment, and treatment. This model is not a rigid therapeutic modality, but provides a contextual lens to build a strong, culturally grounded therapeutic relationship. It is a flexible model and can align with many therapeutic modalities, including a contextual behavioral approach to therapy. Read More.


Truffle Hunting: Bringing Values to Life in the Therapy Room

Jenna LeJeune, PhD
February 25, 2022 from 12pm-2:00pm

This brief workshop is designed to help clinicians deepen their values work with clients by shifting the focus from the content of values conversations to the quality of those conversation. By listening for and deepening the qualities of effective values conversations participants will get a taste for how more experiential and relationally-based values work can supercharge therapy. Participants will have opportunities to both observe demonstrations and practice in small groups with the benefit of feedback. Read More.


Values Prototyping: Using Action to Help Clients Explore Their Values

Jenna LeJeune, PhD
March 11, 2022 from 12pm-2:00pm

This workshop will focus on one specific experiential tool called “values prototyping” that helps clients learn more about their values through engaging in intentional valuing. As participants will hopefully already have a solid foundation of some of the core concepts of the values process in ACT, this workshop will dive right in on how to use values prototyping to help clients learn more about what they would choose to value in their life. You will have the chance to practice developing a values prototype in small groups with the benefit of feedback, so that by the end of the workshop you will be able to use this tool in your work with clients. Read More.


The Invitation to Change Approach: Helping Families Affected by Addiction

Jeff Foote, PhD and Cordelia Kraus, LPC, CADC 1, certified CRAFT clinician
May 13th and 14th, 2022 from 9:00am-5:00pm
at University of Portland, Terrace Room
This two-day in-person workshop will provide skills training for professionals focused on the process of working with clients who have a loved one struggling with substance use issues. The Invitation to Change Approach draws on CRAFT (Community Reinforcement and Family Training), MI (Motivational Interviewing), and ACT (Acceptance and Commitment Therapy) to provide a compassionate and collaborative way of working with the families and concerned significant others of people who struggle with substance use. Read More.


Therapy and Research in Psychedelic Science (TRIPS) Seminar Series

Second Friday of each month from 12:00 PM – 1:00 PM (PT)

TRIPS is an online seminar series that hosts speakers discussing science-informed presentations and discussions about psychedelics to educate healthcare professionals. This series was created to guide healthcare providers and students preparing to be professionals towards the most relevant, pragmatic, and essential information about psychedelic-assisted therapy, changing legal statuses, and harm reduction approaches in order to better serve clients and communities. This seminar series is a fundraiser for our clinical trial of MDMA-assisted psychotherapy for social anxiety disorder that Portland Psychotherapy investigators are preparing for and starting in the Fall of 2021. All proceeds after presenter remuneration will go to fund this clinical trial. Read more.

January 14th, 2022Psilocybin-Assisted Therapy of Major Depressive Disorder using Acceptance and Commitment Therapy as a Therapeutic Frame with Jordan Sloshower, MD, MSc

February 11th, 2022 – Drug-Drug Interactions Between Psychiatric Medications and MDMA or Psilocybin with Aryan Sarparast, MD

May 13th, 2022Implementing Culturally-Attuned & Anti-Racist Psychedelic Therapy: Impact over Intention with Jamilah R. George, M.Div, M.S.